Latest Search
Quote
| Back Zoom + Zoom - | ||||
|
Zai Lab (09688.HK) Enters Global Collaboration with Amgen (AMGN.US) to Explore Novel ADC and BiTE Combination Therapy
Recommend 2 Positive 2 Negative 0 |
||||
|
||||
|
Zai Lab (09688.HK) announced that it has entered into a global clinical research collaboration with Amgen (AMGN.US) to evaluate Zai Labs clinical-stage delta-like ligand 3 (DLL3)-targeted antibody-drug conjugate Zocilurtatug Pelitecan (zoci, formerly known as ZL-1310) in combination with Amgens IMDELLTRA?(tarlatamab), a DLL3-targeted bispecific T-cell engager (BiTE? therapy, for the treatment of patients with extensive-stage small cell lung cancer (ES-SCLC). As part of the collaboration agreement, Amgen will sponsor a global Phase 1b study to assess the safety and efficacy of zoci in combination with IMDELLTRA?in patients with ES-SCLC. Zai Lab will retain full ownership of zoci and will supply the investigational drug for the clinical study to Amgen. Dr. Rafael G. Amado, President and Head of Global Research and Development at Zai Lab, stated that this dual-target combination strategy is expected to enhance systemic and intracranial response rates and depth of response, address resistance mechanisms, and establish a new treatment paradigm for patients with small cell lung cancer. The two therapies leverage complementary mechanisms of action. (ec/u) This article was automatically translated by AI, the Chinese version should be considered the authoritative version. AASTOCKS.com Limited does not guarantee its accuracy or completeness and accepts no liability for any damages or losses arising from the use of this translation. Auto-translated by AI AASTOCKS Financial News |
||||
Copied to Clipboard
 |
||||
